Tango Therapeutics, Inc.

TNGX
$30.64 (+ $0.52 + 1.73%)
Last updated: 2026-07-09 00:35 UTC
TNGX Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS87583X1090
CUSIP87583X109
Market Price30.64
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.91
Market Cap$1.2B
Book Value1.43
Price to Book6.046
Beta1.72
52w High11.2
52w Low1.03
Next Earnings DateN/A

Tango Therapeutics, Inc. trades under ticker TNGX on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US87583X1090, CUSIP 87583X109. Also searched as Tango Therapeutics.

Related researchTNGX stock priceTNGX share price87583X109Tango Therapeutics stockTango Therapeutics share price
About the Company
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Price History